MSF challenges Novartis's action over Indian patent for imatinibBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39104.718380.AB (Published 25 January 2007) Cite this as: BMJ 2007;334:172
- Ganapati Mudur
- 1New Delhi
The international aid organisation Médicins Sans Frontières has called on the Swiss pharmaceutical company Novartis to withdraw its challenge to the Indian government, which has refused to give the company a patent on its leukaemia drug imatinib (Glivec).
In a case scheduled to be heard in an Indian court next week, Novartis has challenged sections of the Indian patent laws that are seen as an important public health tool by Médicins Sans Frontières, doctors, lawyers, and health activists, because they ensure cheap access to …
Log in using your username and password
Log in through your institution
Sign up for a free trial